Antipseudomonal Treatment Decisions During CF Exacerbation Management

Overview

Journal J Cyst Fibros

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2022 Apr 25

PMID 35466039

Authors

D R VanDevanter

N E West

D B Sanders

M Skalland

C H Goss

P A Flume

S L Heltshe

Affiliations

Soon will be listed here.

Abstract

Background: Cystic fibrosis (CF) pulmonary exacerbation (PEx) treatment guidelines suggest that Pseudomonas aeruginosa (Pa) airway infection be treated with two antipseudomonal agents.

Methods: We retrospectively studied treatment responses for STOP2 PEx treatment trial (NCT02781610) participants with a history of Pa infection. Mean lung function and symptom changes from intravenous (IV) antimicrobial treatment start to Visit 2 (7 to 10 days later) were compared between those receiving one, two, and three+ antipseudomonal classes before Visit 2 by ANCOVA. Odds of PEx retreatment with IV antimicrobials within 30 days and future IV-treated PEx hazard were modeled by logistic and Cox proportional hazards regression, respectively. Sensitivity analyses limited to the most common one-, two-, and three-class regimens, to only IV/oral antipseudomonal treatments, and with more stringent Pa infection definitions were conducted.

Results: Among 751 participants, 50 (6.7%) were treated with one antipseudomonal class before Visit 2, while 552 (73.5%) and 149 (19.8%) were treated with two and with three+ classes, respectively. Females and participants with a negative Pa culture in the prior month were more likely to be treated with a single class. The most common single, double, and triple class regimens were beta-lactam (BL; n = 42), BL/aminoglycoside (AG; n = 459), and BL/AG/fluoroquinolone (FQ; n = 73). No lung function or symptom response, odds of retreatment, or future PEx hazard differences were observed by number of antipseudomonal classes administered in primary or sensitivity analyses.

Conclusions: We were unable to identify additional benefit when multiple antipseudomonal classes are used to treat PEx in people with CF and Pa.

Citing Articles

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.

Hurley M, Smith S, Flume P, Jahnke N, Prayle A Cochrane Database Syst Rev. 2025; 1:CD009730.

PMID: 39831540 PMC: 11744767. DOI: 10.1002/14651858.CD009730.pub3.

STOP Using Corticosteroids in Cystic Fibrosis Pulmonary Exacerbations.

Parkins M, Thornton C Ann Am Thorac Soc. 2024; 21(5):696-698.

PMID: 38691006 PMC: 11109905. DOI: 10.1513/AnnalsATS.202401-118ED.

Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.

Thornton C, Caverly L, Kalikin L, Carmody L, McClellan S, LeBar W Ann Am Thorac Soc. 2023; 21(4):595-603.

PMID: 37963297 PMC: 10995546. DOI: 10.1513/AnnalsATS.202306-576OC.

A year in review (2022): Modulators and COVID19, the story goes on….

Dillenhoefer S, Grogono D, Morales-Tirado A J Cyst Fibros. 2023; 22(2):188-192.

PMID: 36906393 PMC: 9986130. DOI: 10.1016/j.jcf.2023.03.001.

References

Jiang M, Karasawa T, Steyger P . Aminoglycoside-Induced Cochleotoxicity: A Review. Front Cell Neurosci. 2017; 11:308. PMC: 5640705. DOI: 10.3389/fncel.2017.00308. View

Cogen J, Faino A, Onchiri F, Hoffman L, Kronman M, Nichols D . Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations. Clin Infect Dis. 2021; 73(9):1589-1596. PMC: 8563324. DOI: 10.1093/cid/ciab525. View

McLaughlin F, Matthews Jr W, Strieder D, Sullivan B, Taneja A, Murphy P . Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis. 1983; 147(3):559-67. DOI: 10.1093/infdis/147.3.559. View

Konstan M, Morgan W, Butler S, Pasta D, Craib M, Silva S . Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007; 151(2):134-9, 139.e1. DOI: 10.1016/j.jpeds.2007.03.006. View

Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L . Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ. 2004; 328(7441):668. PMC: 381218. DOI: 10.1136/bmj.38028.520995.63. View

Master V, Roberts G, Coulthard K, Baghurst P, Martin A, Roberts M . Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study. Pediatr Pulmonol. 2001; 31(5):367-76. DOI: 10.1002/ppul.1060. View

Liou T, Adler F, FitzSimmons S, Cahill B, Hibbs J, Marshall B . Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001; 153(4):345-52. PMC: 2198936. DOI: 10.1093/aje/153.4.345. View

Smith A, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M . Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr. 1999; 134(4):413-21. DOI: 10.1016/s0022-3476(99)70197-6. View

Balke B, Hogardt M, Schmoldt S, Hoy L, Weissbrodt H, Haussler S . Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis. 2006; 25(1):25-30. DOI: 10.1007/s10096-005-0076-9. View

10.

Aaron S . Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms. Paediatr Respir Rev. 2007; 8(3):256-61. DOI: 10.1016/j.prrv.2007.04.005. View

11.

Holland P, Jahnke N . Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev. 2021; 6:CD002007. PMC: 8220369. DOI: 10.1002/14651858.CD002007.pub5. View

12.

Elphick H, Scott A . Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev. 2016; 12:CD002007. PMC: 6463970. DOI: 10.1002/14651858.CD002007.pub4. View

13.

Ratjen F, Doring G . Cystic fibrosis. Lancet. 2003; 361(9358):681-9. DOI: 10.1016/S0140-6736(03)12567-6. View

14.

Flume P, Wainwright C, Tullis D, Rodriguez S, Niknian M, Higgins M . Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. J Cyst Fibros. 2017; 17(1):83-88. DOI: 10.1016/j.jcf.2017.06.002. View

15.

Konstan M, Wagener J, VanDevanter D, Pasta D, Yegin A, Rasouliyan L . Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. J Cyst Fibros. 2012; 11(5):405-11. PMC: 4086189. DOI: 10.1016/j.jcf.2012.03.009. View

16.

VanDevanter D, Morris N, Konstan M . IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2015; 15(3):372-9. PMC: 4841746. DOI: 10.1016/j.jcf.2015.10.006. View

17.

Padoan R, Cambisano W, Costantini D, Crossignani R, Danza M, Trezzi G . Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis. Pediatr Infect Dis J. 1987; 6(7):648-53. DOI: 10.1097/00006454-198707000-00006. View

18.

LeCleir L, Pettit R . Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients. Pediatr Pulmonol. 2017; 52(8):1000-1005. DOI: 10.1002/ppul.23718. View

19.

Flume P, Mogayzel Jr P, Robinson K, Goss C, Rosenblatt R, Kuhn R . Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009; 180(9):802-8. DOI: 10.1164/rccm.200812-1845PP. View

20.

Smith S, Ratjen F, Remmington T, Waters V . Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2020; 5:CD006961. PMC: 7387858. DOI: 10.1002/14651858.CD006961.pub5. View